Systemic mastocytosis is a heterogeneous group of diseases characterized by an increase in the number of mast cells in various tissues of the body. These cells play a key role in the immune response and inflammatory reactions, and are also involved in allergic processes. The main feature of systemic mastocytosis is the abnormal accumulation of mast cells in the skin, bones, liver, spleen and other organs, which can lead to numerous clinical manifestations. The disease can occur in various forms - from less dangerous with insolation and limited symptoms to more serious ones with manifestations of systemic disorders and even life-threatening conditions. Clinical manifestations of systemic mastocytosis vary and can be caused by both dysfunction of the mast cells themselves and the substances they secrete.
History of the disease and interesting historical facts
Systemic mastocytosis was first described in the medical literature in the early 20th century. However, most publications and studies concerning this disease have appeared only in recent decades. In 1975, clinical criteria for the diagnosis of mastocytosis were proposed, although they remained limited. The study of genetic mutations associated with systemic mastocytosis has become an active area of scientific interest in the last 20 years, which has allowed for a deeper understanding of the pathogenesis of the disease. An interesting historical fact is that mastocytosis was primarily known as a skin disease, but today its systemic manifestations are attracting serious attention, which is changing the perception of this condition in medicine.
Epidemiology
Systemic mastocytosis is a rare disease. According to studies, its prevalence is about 5-6 cases per 100,000 people. The disease can occur in people of any age, but is most common in adults, especially men. Notably, there has been an increase in cases of systemic mastocytosis in recent years, which may be due to improved diagnostic methods and increased awareness among doctors. Despite this, the exact incidence of the disease may vary by region depending on the availability of diagnostic technologies and the overall incidence rate.
Genetic predisposition to this disease
Systemic mastocytosis is often associated with mutations in the KIT gene, which encodes a tyrosine kinase receptor. About 90% cases of systemic mastocytosis have such mutations, which serves as a biomarker for diagnosing the disease. In addition, mutations associated with other genes such as TET2 and ASXL1 have also been reported. These mutations may lead to abnormal proliferation of mast cells and impairment of their function. Genetic predisposition to systemic mastocytosis may also be associated with polymorphisms in other genes involved in the regulation of cell growth and differentiation.
Risk factors for the development of this disease
Among the risk factors that contribute to the development of systemic mastocytosis, the following can be distinguished:
- Genetic predisposition - the presence of cases of the disease in the family.
- Existing allergic conditions such as asthma and eczema, which may increase the likelihood of mastocytosis.
- Exposure to chemicals such as asbestos or carcinogens, which can affect bone marrow cells.
- Certain infectious diseases have been shown to trigger increased mast cell activation.
- Retroviral infections, as they can affect cellular immune function and activate mast cells.
Diagnosis of this disease
Diagnosis of systemic mastocytosis includes several stages and methods:
- The main symptoms may include skin manifestations (urticaria, itching), gastrointestinal disorders, pain syndromes and anaphylactic reactions.
- Laboratory tests often include mycaserin and tryptase levels, as well as a bone marrow biopsy to confirm mast cell enlargement.
- Radiological tests such as CT or MRI may be used to evaluate internal organ damage and enlargement of the spleen or liver.
- Other types of diagnostic testing may include testing for markers such as CD117, which help identify abnormal mast cells.
- Differential diagnosis is important to exclude other conditions such as allergy or lymphoma, which requires a more in-depth analysis of the patient's history and clinical manifestations.
Treatment
Treatment for systemic mastocytosis is aimed at controlling symptoms and reducing the number of mast cells in the body:
- General treatment involves avoiding triggers that may cause flare-ups, such as alcohol and certain foods.
- Pharmacological treatment often consists of antihistamines to control allergic reactions and glucocorticosteroids to reduce inflammation.
- Surgical treatment may be required in case of large tumors or significant damage to internal organs.
- Other treatments include immunotherapy and targeted drugs such as imatinib, which are used when specific mutations are present.
List of medications used to treat this disease
There are different classes of drugs used in the treatment of systemic mastocytosis:
- Antihistamines (astemizole, loratadine).
- Glucocorticosteroids (prednisolone, methylprednisolone).
- Targeted drugs (imatinib, nilaotinib).
- Drugs for symptomatic treatment (promethazine, zantac).
- Immunosuppressants (azathioprine, mesalazine).
Disease monitoring
Monitoring of systemic mastocytosis involves regular observation of the patient's condition to identify possible complications:
- Monitoring steps include periodic blood tests to assess tryptase levels and mast cell markers.
- The prognosis depends on the number and activity of mast cells, as well as the presence of transformation into more aggressive forms of the disease.
- Other complications may include anemia, thrombocytopenia, allergic reactions, and more complex conditions such as systemic infections.
Age-related features of the disease
Systemic mastocytosis may present differently depending on age group:
- In children, limited forms are more often observed, often without systemic complications, and symptoms can be limited to skin manifestations.
- In adults, the disease can be more severe, with a tendency for systemic lesions and a high risk of complications.
- In elderly patients, systemic mastocytosis is often combined with other diseases, which complicates diagnosis and therapy.
Questions and Answers
- What is systemic mastocytosis?
Systemic mastocytosis is a disease associated with an increase in the number of mast cells in various tissues of the body, which can cause various clinical manifestations and requires specific diagnosis and treatment. - What are the main symptoms of systemic mastocytosis?
The main symptoms include skin manifestations (urticaria, itching), gastrointestinal disorders, pain syndrome and the risk of anaphylactic reactions. - How to diagnose systemic mastocytosis?
Diagnosis includes blood tests, bone marrow biopsy, radiological studies, and allergy testing. - How is systemic mastocytosis treated?
Treatment is aimed at controlling symptoms using antihistamines, glucocorticosteroids and targeted therapy depending on the presence of mutations. - What is the prognosis for patients with systemic mastocytosis?
The prognosis varies depending on the aggressiveness of the disease and the presence of concomitant complications, but if the recommendations of the treating physicians are followed, significant adaptation to life with this condition is possible.
